Compare Alliant Energy Corporation (LNT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Sanofi SA — how do they compare? Alliant Energy Corporation trades at $72.44 (market cap $19.10B), while Sanofi SA trades at $43.9 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 5.5× Alliant Energy Corporation's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| LNT | SNY | |
|---|---|---|
Market Cap | $19.10B | $104.83B |
Sector | Utilities | Health |
52-Week High | $78.03 | $52.34 |
52-Week Low | $63.62 | $41.33 |
Enterprise Value | $30.83B | $121.32B |
Dividend Yield | 2.89% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $73.96, down 1.16% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported Q1 2026 EPS of $0.82, beating expectations, and maintains a net income margin of 18.58%. Recent news highlights its $13.4 billion clean energy investment plan aimed at capitalizing on data center demand growth.
The outlook for LNT is positive, supported by steady earnings growth, a strong dividend yield, and strategic investments in renewable energy. Key risks include rising debt levels and exposure to regulatory changes in the utilities sector. Analyst sentiment is bullish with no sell ratings, indicating confidence in the company's long-term growth trajectory.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
